2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…2020 American Transplant Congress
Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients
*Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2…2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…2020 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
University of Toledo, Toledo, OH
*Purpose: The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…2020 American Transplant Congress
Basiliximab vs Antithymocyte Globulin Induction with Early Steroid Withdrawal in Kidney Transplant Recipients: Early Rejection Outcomes
*Purpose: Steroid withdrawal within the first month of kidney transplant (KT) remains controversial and has demonstrated a higher risk of acute rejection. The impact of…2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…2020 American Transplant Congress
Pediatric Primary Kidney Transplant Recipients Outcomes by Immunosuppression Induction Received in the United States
*Purpose: Induction immunosuppression types for pediatric transplant recipients vary widely by transplant centers. We sought to study the impact of different induction types on recipients…2020 American Transplant Congress
Differences in Alemtuzumab Dosing Does Not Affect Early Kidney Transplant Outcomes
Wake Forest Baptist Health, Winston-Salem, NC
*Purpose: Alemtuzumab (Alem) is a widely used medication for induction therapy in kidney transplantation. However, there is limited evidence comparing outcomes with low versus high…2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 31
- Next Page »